Can empagliflozin (Jardiance) be started in a patient with an estimated glomerular filtration rate of 27 mL/min/1.73 m²?

Can Empagliflozin Be Started at eGFR 27?

No, empagliflozin should not be initiated at an eGFR of 27 mL/min/1.73 m² for glycemic control, but it CAN be initiated at this eGFR for cardiovascular and kidney protection in patients with type 2 diabetes and chronic kidney disease.

Context-Specific Recommendations

The answer depends critically on your indication:

For Glycemic Control Alone

• Do not initiate empagliflozin at eGFR 27 for glucose lowering 1
• The FDA label explicitly states initiation is not recommended with eGFR <30 mL/min/1.73 m² for glycemic control 1
• Glucose-lowering efficacy is minimal at eGFR <45 mL/min/1.73 m² due to the drug's mechanism of action 2

For Cardiovascular/Kidney Protection

• Yes, you can initiate empagliflozin at eGFR 27 if the patient has:
  • Type 2 diabetes with CKD, OR
  • Heart failure (with eGFR ≥20 mL/min/1.73 m²)

The 2022 ADA/KDIGO consensus guideline explicitly recommends initiating SGLT2 inhibitors with proven kidney or cardiovascular benefit in patients with type 2 diabetes, CKD, and eGFR ≥20 mL/min/1.73 m² 2. This represents a major shift from older labeling that restricted initiation below eGFR 45.

Evidence Supporting Initiation at eGFR 27

The recommendation to initiate at eGFR ≥20 is based on:

• EMPA-KIDNEY trial: Enrolled patients with eGFR as low as 20 mL/min/1.73 m² and demonstrated a 28% reduction in kidney disease progression or cardiovascular death (HR 0.72,95% CI 0.64-0.82) 3
• EMPEROR trials: Showed efficacy and safety in heart failure patients with eGFR ≥20 mL/min/1.73 m² 2
• Subgroup analyses from CREDENCE and DAPA-CKD trials confirmed benefits in patients with baseline eGFR <30 mL/min/1.73 m² 2

Critical Distinction: FDA Label vs. Guidelines

There's an important divergence here:

• FDA label (2026): States "insufficient data to support a dosing recommendation in patients with eGFR below 20 mL/min/1.73 m²" and notes use for glycemic control is not recommended when eGFR <30 1
• 2022 ADA/KDIGO Guidelines: Recommend initiation at eGFR ≥20 for cardiorenal protection, noting the FDA label "reflects package inserts rather than guidance from this consensus report" 2

The guidelines take precedence here because they incorporate more recent trial data (EMPA-KIDNEY, EMPEROR) that postdated the original FDA approval.

Practical Initiation Algorithm at eGFR 27

Step 1: Confirm Indication

• Type 2 diabetes with CKD? → Proceed
• Heart failure? → Proceed
• Glycemic control only without above? → Choose alternative agent

Step 2: Assess Volume Status

• Check for volume depletion, hypotension, or concurrent high-dose diuretics
• If volume depleted: correct first before initiating 2
• Consider reducing loop/thiazide diuretic dose proactively 2

Step 3: Start Empagliflozin 10 mg Daily

• Use 10 mg dose (not 25 mg) at this eGFR level 2
• The 25 mg dose offers no additional benefit at low eGFR and is not more effective for glucose lowering 2

Step 4: Adjust Background Medications

• Insulin users: Maintain at least low-dose insulin to reduce ketoacidosis risk 2
• Sulfonylureas: Consider dose reduction to prevent hypoglycemia 2
• Generally, adjustment is not required for most patients, but reassess at follow-up 2

Step 5: Patient Education

• Counsel on genital hygiene to reduce mycotic infection risk 2
• Implement sick-day protocol: hold empagliflozin during acute illness, prolonged fasting, or surgery 2, 4
• Educate on ketoacidosis symptoms (nausea, vomiting, abdominal pain) even with normal glucose 2

Step 6: Monitor After Initiation

• Expect an initial eGFR drop of 3-5 mL/min/1.73 m² within first 4 weeks—this is hemodynamic and reversible 2, 5
• Do not discontinue for this expected dip 2, 4
• Reassess volume status, blood pressure, and electrolytes at 2-4 weeks
• Monitor for urinary tract infections (higher risk in elderly) 1

Step 7: Continue Even If eGFR Falls Further

• Once initiated, continue empagliflozin even if eGFR drops below 20 mL/min/1.73 m² 2, 4
• Only discontinue if: not tolerated, dialysis initiated, or acute kidney injury occurs 2, 4

Common Pitfalls to Avoid

1. Don't confuse glycemic indication with cardiorenal indication: The eGFR thresholds differ significantly
2. Don't stop for expected eGFR dip: The initial 4-week decline reflects beneficial hemodynamic changes (reduced intraglomerular pressure) 5
3. Don't forget sick-day planning: Ketoacidosis risk, though low, is serious—patients must know to hold the drug during illness 2
4. Don't overlook volume status: Elderly patients (≥75 years) have higher volume depletion risk 1

Special Considerations at eGFR 27

• Glucose-lowering effect will be minimal at this eGFR—set appropriate expectations 2
• Kidney and cardiovascular benefits are preserved regardless of glucose-lowering efficacy 2
• The evidence is strongest if the patient also has albuminuria or heart failure, though benefits appear consistent without these conditions 2
• Increased serum phosphorus may occur—monitor if clinically relevant 6

Alternative SGLT2 Inhibitors at eGFR 27

If empagliflozin is unavailable:

• Dapagliflozin: Can be initiated at eGFR ≥25 mL/min/1.73 m² 2
• Canagliflozin: Initiation not recommended at eGFR <30, but may continue 100 mg if already on therapy 2

Bottom line: At eGFR 27, empagliflozin 10 mg daily can and should be initiated for cardiorenal protection in patients with type 2 diabetes and CKD, based on strong guideline recommendations from ADA/KDIGO 2022 and robust trial evidence from EMPA-KIDNEY 2, 3.